Año 2023 / Volumen 115 / Número 8
Original
Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study

444-449

DOI: 10.17235/reed.2022.9101/2022

María Dolores Martín Arranz, Laura García-Ramírez, Eduardo Martín Arranz, Dolores Montero Vega, José Luis Rueda García, María Sánchez-Azofra, Joaquín Poza Cordón, Jesús Noci Belda, Tamara Verges Martínez-Meco, Paula Blanco San Miguel, Cristina Suárez-Ferrer,

Resumen
Background and aims: response to the SARS-CoV-2 vaccine can be altered in patients with immune-mediated diseases, such as inflammatory bowel disease, and in patients under immunosuppressive treatment. The aims of this study were to evaluate the serologic response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease, to analyze the influence of immunosuppressive drugs on response, and to describe any adverse events in this population. Methods: this was a prospective study that included adult patients with inflammatory bowel disease. Baseline characteristics, concomitant treatments and previous COVID-19 symptoms were collected. Patients underwent serological testing before the first and after the second vaccine dose. Results: a total of 265 patients were consecutively included. Patients received one of the following vaccines: messenger RNA vaccines from Pfizer/BioNTech and Moderna; and adenovirus vaccines from AstraZeneca and Janssen. All adverse events were mild, and the most frequent was injection site pain in 141 (86 %) patients. The seroconversion rate according to the treatment that patients were receiving was: 100 % for those without treatment, 92.5 % for patients treated with mesalazine, 90.3 % for those receiving immunomodulators, 88.9 % for patients with biological monotherapy and 92.5 % for patients on combined treatment. The generation of antibodies according to the vaccine administered was: Pfizer 92.9 %, Moderna 93.3 %, AstraZeneca 98.4 %, and Janssen 12.5 %. Conclusion: the antibody response after vaccination against SARS-CoV-2 is high in patients with inflammatory bowel disease. However, patients treated with immunosuppressive or biologic drugs had a lower response. Adverse events were frequent, but not serious.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Artículos relacionados

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Imagen en Patología Digestiva

Colangiopatía post-COVID: hallazgos ultrasonográficos y de CPRE

DOI: 10.17235/reed.2022.9218/2022

Imagen en Patología Digestiva

Acute respiratory failure secondary to megaesophagus: think beyond COVID-19

DOI: 10.17235/reed.2022.8847/2022

Carta

COVID-19 vaccine and autoimmune hepatitis

DOI: 10.17235/reed.2022.8837/2022

Carta

Abdomen agudo quirúrgico y vacunación de COVID-19

DOI: 10.17235/reed.2022.8721/2022

Carta

Hepatitis AMA positivo inducida por la vacuna contra SARS-CoV-2

DOI: 10.17235/reed.2022.8533/2021

Carta

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Carta

COVID-19 and aorto-enteric fistula

DOI: 10.17235/reed.2021.8272/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Carta

Hepatitis autoinmune desencadenada por la COVID-19

DOI: 10.17235/reed.2021.8045/2021

Carta

Neumoperitoneo y COVID-19. ¿Una asociación causal?

DOI: 10.17235/reed.2021.7877/2021

Carta

COVID-19 and the liver: the chicken or the egg dilemma

DOI: 10.17235/reed.2021.7861/2021

Carta

Daño pancreático: pancreatitis aguda en pacientes COVID-19

DOI: 10.17235/reed.2021.7807/2021

Editorial

Gobernar en tiempos turbulentos con afán de servir

DOI: 10.17235/reed.2020.7684/2020

Carta

Pancreatic injury in COVID-19: pathogenesis and challenges

DOI: 10.17235/reed.2020.7541/2020

Carta

SARS-CoV-2 and acute pancreatitis: a new etiological agent?

DOI: 10.17235/reed.2020.7481/2020

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Carta

COVID-19. Immunothrombosis and the gastrointestinal tract

DOI: 10.17235/reed.2020.7292/2020

Carta

Efecto del Adacolumn® en colitis ulcerosa con COVID-19

DOI: 10.17235/reed.2020.7156/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Revisión

Neoplasia intraepitelial anal: una revisión de conjunto

DOI: 10.17235/reed.2015.3788/2015

Instrucciones para citar
Martín Arranz M, García-Ramírez L, Martín Arranz E, Montero Vega D, Rueda García J, Sánchez-Azofra M, et all. Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study. 9101/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 853 veces.
Este artículo ha sido descargado 79 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 28/07/2022

Aceptado: 15/12/2022

Prepublicado: 16/01/2023

Publicado: 26/07/2023

Tiempo de revisión del artículo: 111 días

Tiempo de prepublicación: 172 días

Tiempo de edición del artículo: 363 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas